Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma

被引:90
|
作者
Agnelli, Luca [2 ,3 ]
Mereu, Elisabetta [1 ]
Pellegrino, Elisa [1 ]
Limongi, Tania [1 ]
Kwee, Ivo [4 ,5 ]
Bergaggio, Elisa [1 ]
Ponzoni, Maurilio [6 ,7 ]
Zamo, Alberto [8 ]
Iqbal, Javeed [9 ]
Piccaluga, Pier Paolo [10 ]
Neri, Antonino [2 ,3 ]
Chan, Wing C. [9 ]
Pileri, Stefano [10 ]
Bertoni, Francesco [4 ,11 ]
Inghirami, Giorgio [1 ,12 ,13 ]
Piva, Roberto [1 ,12 ,13 ]
机构
[1] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Ctr Expt Res & Med Studies, I-10126 Turin, Italy
[2] Osped Maggiore Policlin, Fdn Ist Ricovero & Cura Carattere Sci Ca Granda, Milan, Italy
[3] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[4] Oncol Res Inst, Lymphoma & Genom Res Program, Bellinzona, Switzerland
[5] Dalle Molle Inst Artificial Intelligence, Manno, Switzerland
[6] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy
[7] Ist Sci San Raffaele, Lymphoid Malignancies Unit, I-20132 Milan, Italy
[8] Univ Verona, Dept Pathol, I-37100 Verona, Italy
[9] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[10] Univ Bologna, Inst Hematol & Med Oncol, S Orsola Malpighi Hosp, Bologna, Italy
[11] Oncol Inst So Switzerland, Lymphoma Unit, Bellinzona, Switzerland
[12] NYU, Sch Med, Ctr Canc, New York, NY USA
[13] NYU, Sch Med, Dept Pathol, New York, NY USA
关键词
PERIPHERAL T-CELL; GENE-EXPRESSION ANALYSIS; KINASE; CLASSIFICATION; ABERRATIONS; PROFILE;
D O I
10.1182/blood-2012-01-405555
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anaplastic large-cell lymphomas (ALCLs) are a group of clinically and biologically heterogeneous diseases including the ALK(+) and ALK(-) systemic forms. Whereas ALK(+) ALCLs are molecularly characterized and can be readily diagnosed, specific immunophenotypic or genetic features to define ALK(-) ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) remains controversial. In the present study, we undertook a transcriptional profiling meta-analysis of 309 cases, including ALCL and other primary T-NHL samples. Pathway discovery and prediction analyses defined a minimum set of genes capable of recognizing ALK(-) ALCL. Application of quantitative RT-PCR in independent datasets from cryopreserved and formalin-fixed paraffin-embedded samples validated a 3-gene model (TNFRSF8, BATF3, and TMOD1) able to successfully separate ALK(-) ALCL from peripheral T-cell lymphoma not otherwise specified, with overall accuracy near 97%. In conclusion, our data justify the possibility of translating quantitative RT-PCR protocols to routine clinical settings as a new approach to objectively dissect T-NHL and to select more appropriate therapeutic protocols. (Blood. 2012;120(6):1274-1281)
引用
收藏
页码:1274 / 1281
页数:8
相关论文
共 50 条
  • [41] Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia
    Ahmed, Reham
    Feldman, Andrew L.
    BLOOD, 2024, 143 (10) : 938 - 938
  • [42] Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma
    Hu, G.
    Dasari, S.
    Asmann, Y. W.
    Greipp, P. T.
    Knudson, R. A.
    Benson, H. K.
    Li, Y.
    Eckloff, B. W.
    Jen, J.
    Link, B. K.
    Jiang, L.
    Sidhu, J. S.
    Wellik, L. E.
    Witzig, T. E.
    Bennani, N. N.
    Cerhan, J. R.
    Boddicker, R. L.
    Feldman, A. L.
    LEUKEMIA, 2018, 32 (02) : 565 - 569
  • [43] Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma
    Hapgood, Greg
    Ben-Neriah, Susana
    Mottok, Anja
    Lee, Derrick G.
    Robert, Kridel
    Villa, Diego
    Sehn, Laurie H.
    Connors, Joseph M.
    Gascoyne, Randy D.
    Feldman, Andrew L.
    Farinha, Pedro
    Steidl, Christian
    Scott, David W.
    Slack, Graham W.
    Savage, Kerry J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (03) : E28 - E31
  • [44] Pathobiology of ALK+ anaplastic large-cell lymphoma
    Amin, Hesham M.
    Lai, Raymond
    BLOOD, 2007, 110 (07) : 2259 - 2267
  • [45] PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
    Atsaves, V.
    Tsesmetzis, N.
    Chioureas, D.
    Kis, L.
    Leventaki, V.
    Drakos, E.
    Panaretakis, T.
    Grander, D.
    Medeiros, L. J.
    Young, K. H.
    Rassidakis, G. Z.
    LEUKEMIA, 2017, 31 (07) : 1633 - 1637
  • [46] PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
    V Atsaves
    N Tsesmetzis
    D Chioureas
    L Kis
    V Leventaki
    E Drakos
    T Panaretakis
    D Grander
    L J Medeiros
    K H Young
    G Z Rassidakis
    Leukemia, 2017, 31 : 1633 - 1637
  • [47] Refractory Case of ALK-Negative Anaplastic Large-Cell Lymphoma with PAX-5 Expression and T-Cell Receptor-gamma Gene Rearrangement
    Kawakami, Keiki
    Yazaki, Akira
    Ito, Ryugo
    Tono, Yasutaka
    Murata, Tetsuya
    Baba, Yohichiro
    Uchiyama, Tomoko
    Imai, Hiroshi
    Nakamura, Shigeo
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2013, 53 (03) : 251 - 254
  • [48] BRENTUXIMAB VEDOTIN FOR T-CELL LYMPHOMA: A CASE OF ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
    Sumbly, V.
    Landry, I.
    Rizzo, V.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (04) : 1155 - 1155
  • [49] Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma
    Merkel, Olaf
    Hamacher, Frank
    Laimer, Daniela
    Sifft, Eveline
    Trajanoski, Zlatko
    Scheideler, Marcel
    Egger, Gerda
    Hassler, Melanie R.
    Thallinger, Christiane
    Schmatz, Ana
    Turner, Suzanne D.
    Greil, Richard
    Kenner, Lukas
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (37) : 16228 - 16233
  • [50] Primary bone anaplastic large cell lymphoma of lymphohistiocytic variant, ALK-negative: A challenging diagnosis
    Karube, Kennosuke
    Nakada, Norihiro
    Yamamoto, Hidetaka
    PATHOLOGY INTERNATIONAL, 2020, 70 (06) : 376 - 378